Peri-orbital & Peri-oral Wrinkle Reduction Trial

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This is prospective, multi-center, single-blinded, non-randomized clinical trial. Enrolled subjects will receive two Ulthera® treatments on the peri-orbital and peri-oral regions, each treatment provided 30 days apart. Follow-up visits will occur at 90 and 180 days following treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01813760` - Treatment of Periorbital and Perioral Wrinkles With the Applications of the Iluminage Diode Laser	N/A
	Completed	`NCT05299619` - Tixel Treatment for Dry Eye Symptoms	N/A

NCT number	NCT01981252
Study type	Interventional
Source	Merz Pharmaceuticals, LLC
Contact
Status	Terminated
Phase	N/A
Start date	October 2013
Completion date	August 2014

Peri-orbital and Peri-oral Wrinkle Reduction Trial

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms